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Abstract
Background: Renal biopsy is not free from complications and patients who undergo this procedure are usually
hospitalized to receive intensive care for several days after biopsy. In contrast, after this period, routine follow-up to
detect biopsy-associated complications is rarely scheduled, unless the patient develops a clinical manifestation. We
describe a case of marked enlargement of arteriovenous fistula in the kidney that occurred many years after renal
biopsy. In contrast to the previous cases requiring interventional radiology, our patient showed subclinical growth
of fistula over about nine years.
Case presentation: A 24-year-old man with a history of percutaneous renal biopsy was hospitalized for interventional
radiology. Gross hematuria emerged shortly after biopsy, but completely disappeared with administration of
hemostatic agents and bed rest. Subsequently, the patient had few symptoms for many years. A giant fistula
(a gourd-shaped mass, size 26 × 22 and 12 × 11 mm) was unexpectedly detected by ultrasonography performed for
examination of an unrelated disorder (slight elevation of serum transaminase) at 9 years after the original biopsy. The
fistula was successfully treated with radiological intervention. Thus, subclinical development of complications
associated with renal biopsy should be considered, even in an uneventful course.
Conclusions: This case provides a platform to discuss the importance of long-term follow-up of patients after renal
biopsy despite of its difficulty.
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Background
Renal biopsies provide critical clues in diagnosis of renal
diseases. However, this procedure is not free from com-
plications, despite technical improvements over time. A
recent nationwide study in Norway showed gross
hematuria after biopsy in 1.9 % of patients, with 0.9 %
needing blood transfusion and 0.2 % requiring surgical
intervention or catheterization [1]. There have also been
several reports of renal arteriovenous fistula (AVF) after
renal biopsy. In most such cases, radiological interven-
tions were performed due to severe clinical manifestations
of gross hematuria [2–4], hemorrhagic shock [2], severe
hypertension [2, 5], and decline of renal function [4],
which all emerged shortly after the biopsy. We herein re-
port a case of marked enlargement of renal AVF that was
detected by chance nine years after biopsy and was suc-
cessfully treated with interventional radiology (IR). In con-
trast to the previous cases of renal AVF associated with
biopsy [2–6], our patient showed subclinical growth of
AVF over about nine years. Thus, this case provides a plat-
form to discuss the importance of long-term follow-up of
patients after renal biopsy.
Case presentation
A 24-year-old man was admitted to our facility for IR.
The patient had a history of percutaneous kidney biopsy
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under real-time ultrasound guidance using a cutting
needle at 15 years of age. Macroscopic hematuria started
shortly after biopsy, but ceased within a couple of days
without development of significant anemia. The size of a
subcapsular hematoma (up to 38 mm long by 7 mm
wide), which occurs in most renal biopsies, also de-
creased over time. Thus, common complications such as
gross hematuria and subcapsular hematoma occurred,
but were settled within days of the biopsy. Based on our
institutional protocol, the patient was discharged 7 days
after biopsy. However, immediate rehospitalization was
required on the day of discharge due to abrupt onset of
severe left flank pain. Gross hematuria reemerged and
was intermittently observed for several days, resulting in
hypotension (94/58 mmHg), a significant decrease of
blood hemoglobin (14.2 to 10.7 g/dl), and acute dysuria.
Embolization via IR was considered as an emergency
therapy to stop bleeding, but gross hematuria eventually
disappeared within days with intravenous injection of
hemostatic agents such as carbazochrome sodium sul-
fonate and tranexamic acid, in addition to bed rest. It
was noteworthy that color-coded Doppler US detected
AVF as a mosaic signal in the lower pole of the left kid-
ney (Fig. 1a), which was the puncture site of the biopsy.
However, in terms of size, this lesion was morphologic-
ally undetectable, even by dynamic contrast-enhanced
computed tomography (CT) (Fig. 1b). After disappear-
ance of gross hematuria, the patient was free from renal
AVF-related manifestations, including abdominal pain,
hypertension, and renal impairment. Thus, it was deter-
mined that IR was not required at this time.
IgA nephropathy was diagnosed based on the findings
of renal biopsy. The patient was hospitalized again six
months later to receive steroid pulse therapy followed by
tonsillectomy [7] for this glomerulopathy. A striking im-
provement in urinary abnormalities was gradually
achieved, with urinary protein reduced from 4.2 to 0.2 g/
day and red blood cells decreased to a level of 5 cells per
high-power field in sediment. Ultrasound examination
was performed again, but growth of renal AVF was not
evident in this period. Following the combination ther-
apy, the patient regularly visited our hospital and took
300 mg dipyridamole and 6 mg candesartan orally each
day. The angiotensin II receptor antagonist was pre-
scribed as a renoprotective agent, rather than for a de-
pressor effect. Blood pressure (125/75 mmHg), blood
hemoglobin, and serum creatinine remained normal in
this period and for over eight years.
Despite the uneventful course, at the age of 24 the pa-
tient underwent abdominal ultrasound because of a
slight elevation of serum alanine aminotransferase (up to
36 U/l), which had been noted approximately one year
earlier. Unexpectedly, a mass lesion was found in the left
kidney, whereas there were few morphological abnor-
malities in the liver. Dynamic contrast-enhanced CT
subsequently delineated a gourd-shaped mass (26 × 22
and 12 × 11 mm) in the left kidney (Fig. 2a) and marked
dilatation of the left renal vein (Fig. 2b). Three-
dimensional CT (Fig. 2c) and maximum intensity projec-
tion CT (Fig. 2d) clearly revealed that this lesion directly
led to the renal artery and vein, suggesting that the renal
AVF had grown subclinically to a giant size over many
years and had resulted in marked dilatation of the venous
system. Therefore, IR was required to prevent further
growth of the fistula and manifestation of symptoms.
Transcatheter embolization of high-flow left renal
AVF was performed using detachable coils by radiolo-
gists. The fistula was solidly packed with 7 Coil 400
Standard Complex® coils (Penumbra, Inc., Alameda, CA,
USA) and 22 Presidio® coils (Codman, Inc., Raynham,
MA, USA) under digital subtraction angiography. As
shown in Fig. 3, the high-flow fistula was successfully
blocked out, with conservation of renal blood flow. The
patient was discharged on postoperative day 3 without
adverse events. A follow-up test by contrast-enhanced
MRI at about 3 months after IR showed maintained
Fig. 1 Initial appearance of the AVF. a Color-coded Doppler US shortly after biopsy showed the AVF as a mosaic signal in the lower pole of the
left kidney. b There were morphologically few abnormalities in the vasculature on dynamic contrast-enhanced CT, indicating the small size of this
initial lesion
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discontinuation of blood flow to the AVF (Fig. 4), indi-
cating the success of the treatment.
Conclusions
Complications associated with renal biopsies are not un-
common. Indeed, nephrologists exert extreme caution
early after puncture, especially for the first few days. The
guidelines for renal biopsies published by the Japanese
Society of Nephrology [8] recommend a stay of no less
than 4 to 7 days in hospital. Postural changes in bed and
adoption of a standing position are not allowed for the
first hours and almost the entire first day, respectively,
based on two studies of biopsy-related complications:
Khajehdehi et al. [9] found that patients with stable
hematocrit at 6 h were at low risk for bleeding at
24 h while hospitalized, and Marwah et al. [10] found
that major complications were identifiable in most
cases within 12 h. Thus, intensive management is im-
portant for a short time after renal biopsy. However,
there is little information on appropriate follow-up
for patients with a history of renal biopsy after this
period.
Fig. 2 Contrast-enhanced CT of the enlarged AVF and dilatation of the left renal vein. Two-dimensional (a, b) and three-dimensional (c) CT performed
incidentally at 9 years after biopsy revealed the morphological characteristics of an enlarged left renal AVF (red arrowheads) and dilated
left renal vein (yellow arrows). d A maximum intensity projection image showed a connection with the renal artery and vein. Abbreviations:
A, renal artery; V, renal vein
Fig. 3 Embolization therapy for the renal AVF. a Pre-therapeutic, b early treatment phase, and c post-therapeutic digital subtraction angiography
images. The renal AVF (circled with a solid line) was filled with microcoils (circled with a dashed line) over time. The enlarged left renal
vein (indicated by arrowheads) was delineated despite the arterial phase until the early therapeutic period (a, b), but disappeared after
the AVF was blocked out (c), indicating a large amount of shunt flow
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A number of cases of renal AVF associated with biopsy
[2–6] have been published. In particular, Lorenzen et al.
[6] reported 20 cases of post-biopsy AVF, all of which
were successfully treated with IR. In this report, the inci-
dence of AVF after renal biopsy was 1.6 %, but this rate
is as high as 16 % in other reports. Lorenzen et al. also
highlighted the improvement of renal function after IR,
based on a significant decrease in the mean creatinine
level from 4.4 to 2.7 mg/dl (p = 0.0014). In our case, IR
was initially considered because of gross hematuria, but
was not used in light of the subsequent uneventful
course. Since 70 % of AVFs occlude spontaneously, med-
ical management in anticipation of spontaneous closure
of the fistula may be the best first choice in an asymp-
tomatic patient [6]. In most other IR cases, patients with
renal AVF showed severe clinical manifestations includ-
ing gross hematuria [2–4], hemorrhagic shock [2], severe
hypertension [2, 5], and decline of renal function [4].
The present case raises an issue regarding long-term
follow-up of patients after renal biopsy. This may not be
feasible in practice for all patients and some might not
need regular visits, depending on the diagnosis. How-
ever, our case shows the possibility of subclinical de-
velopment of renal biopsy-associated complications
indicating a subpopulation of patients that requires
periodic examination, even if this is uneventful. Based
on our experience, this subpopulation may include
patients who are younger and who show clinical man-
ifestations shortly after biopsy.
In conclusion, we have reported a case of marked en-
largement of a renal AVF that was found incidentally
9 years after biopsy without clinical manifestations and
was successfully treated with IR.
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